Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance

ABSTRACT: Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance

PROVIDER: PRJNA553592 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance

Project description:Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance

| PRJNA553593 | ENA

Natural Killer Cell Therapies for Hematologic Malignancies

Project description:Natural Killer Cell Therapies for Hematologic Malignancies

| PRJNA776383 | ENA

Germ cell tumor and associated hematologic malignancies

Project description:Germ cell tumor and associated hematologic malignancies

| PRJNA660496 | ENA

Germ cell tumor and associated hematologic malignancies

Project description:Germ cell tumor and associated hematologic malignancies

| PRJNA660497 | ENA

Natural Killer Cell Therapies for Hematologic Malignancies

Project description:Natural Killer Cell Therapies for Hematologic Malignancies

| PRJNA776384 | ENA

Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies

Project description:Renneville A, Gasser JA, Grinshpun DE , Jean Beltran PM, Udeshi ND, Dr. Mary E. Matyskiela , Clayton T, McConkey M, Viswanathan K, Tepper A, Guirguis AA, Sellar RS, Cotteret S, Marzac C, Saada V, de Botton S, Kiladjian J, Cayuela J, Rolfe M, Chamberlain PP, Carr SA, Ebert BL. 2021. Thalidomide analogs exert their therapeutic effects by binding to the CRL4CRBN E3 ubiquitin ligase, promoting ubiquitination and subsequent proteasomal degradation of specific protein substrates. Drug-induced degradation of IKZF1 and IKZF3 in B-cell malignancies demonstrates the clinical utility of targeting disease-relevant transcription factors for degradation. Here, we found that avadomide (CC-122) induces CRBN-dependent ubiquitination and proteasomal degradation of ZMYM2 (ZNF198), a transcription factor involved in balanced chromosomal rearrangements with FGFR1 and FLT3 in aggressive forms of hematologic malignancies. The minimal drug-responsive element of ZMYM2 is a zinc-chelating MYM domain and is contained in the N-terminal portion of ZMYM2 that is universally included in the derived fusion proteins. We demonstrate that avadomide has the ability to induce proteasomal degradation of ZMYM2-FGFR1 and ZMYM2-FLT3 chimeric oncoproteins, both in vitro and in vivo. Our findings suggest that patients with hematologic malignancies harboring these ZMYM2 fusion proteins may benefit from avadomide treatment.

2021-02-18 | MSV000086902 | MassIVE

Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies specifically target the PI3Kgamma isoform

Project description:Development of novel PI3Ks inhibitors is an important strategy to overcome their resistance and poor tolerability in clinical trials. The quassinoid family member Brusatol shows specific inhibitory activity against hematologic malignancies. However, the mechanism of its anti-cancer activity is unknown. We studied the anti-cancer activity of Brusatol on multiple hematologic malignancies derived cell lines by RNA-Seq, mass spectrometry, biochemical pull-down assays, and CRISPR/Cas9 gene knock-out. We demonstrated that the PI3Kgamma isoform was identified as a direct target of Brusatol, and inhibition was lost on PI3Kgamma deficient cells. Novel synthetic analogs were also developed and tested in vitro and in vivo. They shared superior potency in their ability to inhibit malignant hematologic cell lines, and in a xenograft transplant mouse model. They also had minimal toxicity to normal human cells. These new analogs have enhanced potential for development as a new class of PI3K inhibitors for treatment of hematologic malignancies.

2020-03-06 | MSV000085067 | MassIVE

450K analysis of pediatric histiocytic sarcomas and anteceding hematologic malignancies

Project description:450K analysis of pediatric histiocytic sarcomas and anteceding hematologic malignancies

| PRJNA432268 | ENA

Activity of EP300/CBP bromodomain inhibitor CCS1477 across diverse hematologic malignancies

Project description:Activity of EP300/CBP bromodomain inhibitor CCS1477 across diverse hematologic malignancies

| PRJNA854913 | ENA

GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies

Project description:Mutations in the RNA splicing factor gene SF3B1 are common across hematologic and solid cancers and result in widespread alterations in splicing, but therapeutic means to correct this mis-splicing do not exist. Here, we utilize synthetic introns uniquely responsive to mutant SF3B1 to identify trans factors required for aberrant mutant SF3B1 splicing activity. This revealed the G-patch domain-containing protein GPATCH8 as required for mutant SF3B1-induced splicing alterations and impaired hematopoiesis. GPATCH8 is involved in quality control of branchpoint selection, interacts with the RNA helicase DHX15, and functionally opposes SUGP1, a G-patch protein recently implicated in SF3B1-mutant diseases. Silencing of GPATCH8 corrected one-third of mutant SF3B1-dependent splicing defects and was sufficient to improve dysfunctional hematopoiesis in SF3B1-mutant mouse and primary human progenitors. These data identify GPATCH8 as a novel splicing factor required for mis-splicing by mutant SF3B1 and highlight the therapeutic impact of correcting aberrant splicing in SF3B1-mutant cancers.

2024-04-10 | PXD051128 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data